NASDAQ:SPRB Spruce Biosciences Q2 2026 Earnings Report $49.99 -3.71 (-6.91%) Closing price 04:00 PM EasternExtended Trading$49.94 -0.05 (-0.10%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Spruce Biosciences EPS ResultsActual EPS-$6.68Consensus EPS -$5.79Beat/MissMissed by -$0.89One Year Ago EPSN/ASpruce Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASpruce Biosciences Announcement DetailsQuarterQ2 2026Date8/12/2026TimeBefore Market OpensConference Call DateWednesday, August 12, 2026Conference Call Time7:00AM ETUpcoming EarningsSpruce Biosciences' Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, November 11, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Spruce Biosciences Earnings HeadlinesSpruce Biosciences (NASDAQ:SPRB) Coverage Initiated at Lake Street CapitalSeptember 19 at 1:54 AM | americanbankingnews.comLake Street initiates coverage of Spruce Biosciences at buySeptember 18, 2026 | msn.comGold did this exact thing in 1975… [then exploded]In 1975 the Fed raised rates and gold fell 50 percent. Headlines called the gold bull market dead. Instead gold climbed from 100 dollars in 1976 to 850 dollars by 1980, a 750 percent gain in under five years. Today the new Fed chair has floated another rate hike, and investors are reacting the same way they did in 1975. Analyst Garrett Goggin, CFA, CMT, founder of Golden Portfolio, says the setup rhymes with that era.September 22 at 1:00 AM | Golden Portfolio (Ad)Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 8, 2026 | businesswire.comOppenheimer Sticks to Its Buy Rating for Spruce Biosciences (SPRB)August 28, 2026 | theglobeandmail.comSpruce Biosciences stock gains after analyst backs regulatory progressAugust 27, 2026 | finance.yahoo.comSee More Spruce Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Spruce Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spruce Biosciences and other key companies, straight to your email. Email Address About Spruce BiosciencesSpruce Biosciences (NASDAQ:SPRB) is a clinical-stage biopharmaceutical company focused on developing treatments for endocrine disorders. The company’s research has centered on therapies intended to address conditions involving hormone dysregulation and adrenal function. Its lead investigational product is tildacerfont, an oral, selective corticotropin-releasing factor type 1 (CRF1) receptor antagonist. The therapy is designed to reduce excessive adrenocorticotropic hormone (ACTH) signaling and adrenal androgen production, with development focused primarily on congenital adrenal hyperplasia (CAH), a rare inherited disorder affecting cortisol production. Tildacerfont has been evaluated in clinical studies involving patients with both classic and nonclassic forms of CAH. Spruce Biosciences has operated as a U.S.-based company serving the global biopharmaceutical market through clinical development activities and collaborations with research and medical communities. The company does not have a broadly marketed commercial product, and its activities have primarily involved research, clinical trials, regulatory planning and business development related to its endocrine-focused pipeline.View Spruce Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Meta’s Muse Highlights Arm’s Growing Role in AI InfrastructureNucor and Steel Dynamics Just Pulled Back—The Steel Story Still Looks Strong5 Dividend Stocks That Combine Income, Earnings Growth, and Wall Street SupportDespite Record Sales, Texas Roadhouse Has Beef With Beef CostsEncore Capital Group Has Doubled—But Its Best Tailwind Won’t Last ForeverCoach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback3 Retail Stocks Getting Crushed and the Long-Dated Options Trade on Each One Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
